Neurim Pharma Grants Exeltis Marketing Rights For Paediatric Prolonged-Release Melatonin in Spain
Neurim Pharmaceuticals and Exeltis announced a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim’s new Rx ...
Neurim Pharmaceuticals and Exeltis announced a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim’s new Rx ...
To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific, ...
QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s (AD), Parkinson’s ...
Jazz Pharm announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110 , a ...
On February 8th, the EDQM will hold a dedicated session jointly organised with the European Medicines Agency on the role ...
The store has been introduced to provide customers with easy access to research quantities of commercial grade ligands and catalysts, ...
ViiV Healthcare presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq ...
Merck, a leading science and technology company announced that the EMA to request the company for marketing approval for its ...
The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®1, has been accepted for review by the ...
Shire plc announced it has agreed to license global rights to all indications for PF-00547659 from Pfizer Inc. ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.